Abstract |
Galsulfase, a Food and Drug Administration-approved enzyme replacement therapy for mucopolysaccharidosis VI, is administered once weekly in a hospital setting as a 4-hour intravenous infusion. To improve convenience and alleviate family responsibilities associated with clinic visits, some physicians are transitioning appropriate patients to home infusion therapy. An online survey was conducted with 3 physicians treating 4 patients with mucopolysaccharidosis VI to better understand the factors motivating the transition to home infusion therapy, identify characteristics of appropriate candidates, and evaluate the potential impact on the lives of patients and their families. Survey results showed that home infusion may offer patients and their families increased flexibility of schedule and enhanced family life.
|
Authors | Cynthia Tifft, Virginia Proud, Paul Levy, Kristin DeMarco, Helen Nicely, Sean Turbeville |
Journal | Journal of infusion nursing : the official publication of the Infusion Nurses Society
(J Infus Nurs)
2009 Jan-Feb
Vol. 32
Issue 1
Pg. 45-52
ISSN: 1539-0667 [Electronic] United States |
PMID | 19142150
(Publication Type: Journal Article)
|
Chemical References |
- Recombinant Proteins
- N-Acetylgalactosamine-4-Sulfatase
- galsulfase
|
Topics |
- Data Collection
- Home Infusion Therapy
- Humans
- Infusions, Intravenous
- Mucopolysaccharidosis VI
(drug therapy)
- N-Acetylgalactosamine-4-Sulfatase
(administration & dosage, therapeutic use)
- Physicians
- Recombinant Proteins
(administration & dosage, therapeutic use)
- United States
|